AbbVie’s, Ascletis’ protease inhibitors spark skeptical outlook for repurposed activity in Covid-19

7 May 2020 (Last Updated May 7th, 2020 11:31)

Protease inhibitors such as AbbVie’s HIV drug Kaletra (lopinavir/ritonavir) and Ascletis Pharma’s HCV therapy Ganovo (danoprevir) evoke suspicion for their potential in Covid-19, as there is a low probability of an inhibitor being efficient against two separate viruses with distinct structures.

In March, AbbVie said there were unconfirmed media reports that information from China showed Kaletra’s efficacy in Covid-19 but that it did not have access to that data. Read more here.